Michigan State University researcher Roshni Kulkarni has been recognized with a national award for her work treating patients with bleeding and clotting disorders.
The My Life, Our Future Champion Award was awarded to Kulkarni, a pediatric hematologist oncologist, and her team for their work genotyping 95 hemophilia patients over the last two years.
“We are looking for patterns in genotypes to guide us in future treatment and predict bleeding tendencies and other complications,” said Kathleen Anderson, clinical research coordinator for the Center for Bleeding and Clotting Disorders.
Although hemophilia and other bleeding disorders are not curable, genotyping allows patients and health care providers to better understand their mutation and provide more personalized healthcare options.
If they have a bad mutation, we can avoid certain factors in their care. Personalized genotype based medicine is where the world is going, said Kulkarni.
Kulkarni has been working with hemophilia patients for more than 35 years, and says there is a lot to look forward to in the study of bleeding illnesses.
“Genotyping is one more thing adding to better care,” she said.
Kulkarni and her team will accept the award at The World Federation of Hemophilia Congress July 24-28 in Florida.